Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
A phase II study of Gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: A hoosier oncology group study
Higinia R. Cardenes; Annette M. Moore; Cynthia S. Johnson; Menggang Yu; Paul Helft; Elena G. Chiorean; Jacob Vinson; Thomas J. Howard; Anthony W. Stephens; D. Fritz Tai; et al. (Profiled Authors: Paul R. Helft; Patrick J. Loehrer; Higinia R. Cardenes; Thomas J. Howard)
American Journal of Clinical Oncology: Cancer Clinical Trials. 2011;34(5):460-465.Abstract
OBJECTIVE: A Phase II study was conducted at Indiana University to evaluate the safety and efficacy of combined weekly Gemcitabine (GEM) with external beam radiotherapy (RT) in unresectable, locally advanced pancreatic cancer (LAPC). METHODS: Eligible patients had biopsy-proven LAPC without evidence of metastatic disease. In part A of the treatment plan, patients received GEM 600 mg/m IV weekly, with concurrent RT (50.4 Gy in 28 fractions, 1.8 Gy/d, 5 days per week). Part B of the treatment plan began approximately 4 weeks after completing part A: patients without disease progression received weekly GEM 1000 mg/m on days 1, 8, and 15 of a 28-day cycle for 6 cycles or until disease progression. RESULTS: From April 2001 to June 2003, of 28 patients evaluated, 24 (86%) completed part A. About 22 patients had grade 3 toxicities, primarily hematologic (43%) and gastrointestinal (36%). Three patients (11%) had grade 4 toxicities (one each for hyperbilirubinemia, infection, and dyspnea). The median follow-up was 10 months (1-63 months) for all enrolled patients. Six patients (21%) had a radiologic partial response, 16 (57%) had stable disease, 5 (18%) had progressive disease, and 1 patient (4%) had an unevaluable response at last follow-up. Four patients (14%) underwent surgical resection (2 with R0 resection). Median time to progression was 6 months (0-36 months). Median survival time was 10.3 months (95% confidence interval, 7.9-14.6 months). The 1- and 2-year actuarial survival rates were 30% and 11%. At last analysis, all but 2 patients died. CONCLUSION: The activity and toxicity profile of combination GEM and RT indicates that this can be safely administered for patients with LAPC. Copyright © 2011 by Lippincott Williams & Wilkins.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Bedatri Sinha; Fredrick Stehman; Jeanne Schilder; Lori Clark; Higinia CardenesInternational Journal of Gynecological Cancer. 2009;19(4):686-693.
Patrick J. Loehrer Sr.; Yang Feng; Higinia Cardenes; Lynne Wagner; Joanna M. Brell; David Cella; Patrick Flynn; Ramesh K. Ramanathan; Christopher H. Crane; Steven R. Alberts; et al.Journal of Clinical Oncology. 2011;29(31):4105-4112.
M.L. Rothenberg; M.J. Moore; M.C. Cripps; J.S. Andersen; R.K. Portenoy; H.A. Burris III; M.R. Green; P.G. Tarassoff; T.D. Brown; E.S. Casper; et al.Annals of Oncology. 1996;7(4):347-353.
Appears in this Document